Single Use Bioreactors Sales

Single Use Bioreactors Sales Market Outlook

The global Single Use Bioreactors market was valued at approximately USD 6.5 billion in 2022 and is projected to reach around USD 16.8 billion by 2035, growing at a robust CAGR of 8.9% during the forecast period from 2025 to 2035. The escalating demand for biopharmaceuticals and the rapid advancement in biomanufacturing technology are key growth factors contributing to this upward trajectory. Moreover, the increasing preference for single-use systems over traditional bioreactors due to their cost-effectiveness and efficiency in reducing cross-contamination risks enhances operational flexibility. Furthermore, the growing trends towards personalized medicine and the surging investments in biotechnological research and development across various regions are expected to bolster the market growth in the coming years.

Growth Factor of the Market

The growth of the Single Use Bioreactors market is significantly driven by various factors that align with the ongoing changes in the biopharmaceutical landscape. One of the primary drivers is the rising shift towards single-use systems, which offer distinct advantages such as minimized downtime and reduced cleaning validation requirements, thereby streamlining the manufacturing processes. The increasing emphasis on bioprocess optimization to enhance productivity and reduce production costs has led many organizations to adopt single-use bioreactors. Additionally, the COVID-19 pandemic has accelerated research and development in vaccine production, thereby increasing demand for efficient and flexible manufacturing technologies. Furthermore, the global increase in chronic diseases has intensified the need for advanced biopharmaceuticals, necessitating the deployment of more agile and adaptable production methods. These growth factors indicate a promising future for the Single Use Bioreactors market, ensuring sustained advancements in bioprocessing technologies.

Key Highlights of the Market

• Rapid adoption of single-use technologies in biopharmaceutical manufacturing.
• Increased focus on personalized medicine driving demand for flexible bioprocessing solutions.
• Growing investments in biotechnology research and development worldwide.
• Significant advancements in bioreactor design and functionality enhancing operational efficiency.
• Expansion of biopharmaceutical production capabilities in emerging markets.

By Product Type

Stirred Tank Bioreactors:

Stirred Tank Bioreactors are among the most widely used types of single-use bioreactors, owing to their high efficiency in mixing and aeration. These bioreactors offer a controlled environment conducive to cell growth and product formation, making them ideal for both mammalian and microbial cell cultures. The design allows for excellent mass transfer and nutrient distribution, which are critical for optimizing cell yields. Additionally, the scalability of stirred tank systems makes them suitable for both small-scale and large-scale production, thereby catering to the diverse needs of biopharmaceutical companies. The growing trend towards biopharmaceutical production and vaccine development is further propelling the demand for stirred tank bioreactors, as they provide the necessary conditions for efficient bioprocessing.

Wave-Induced Bioreactors:

Wave-Induced Bioreactors utilize gentle, wave-like motions to mix the culture medium, which is particularly beneficial for sensitive cell types. This technology minimizes shear stress on cells, making it suitable for applications such as growing mammalian cells for therapeutic protein production. These bioreactors are increasingly favored in regenerative medicine and cell culture research due to their ability to maintain viable cell populations and promote optimal growth conditions. The flexibility of wave-induced systems allows for easy integration into existing biomanufacturing workflows, enhancing their appeal to organizations aiming to modernize their production capabilities while ensuring cell integrity.

Bubble Column Bioreactors:

Bubble Column Bioreactors operate by introducing gas bubbles into the culture medium, allowing for efficient gas-liquid mass transfer that supports aerobic fermentation processes. These systems are particularly advantageous for microbial cultures that require oxygen and are widely used in the production of biofuels and biochemicals. The simplicity of the design and ease of operation make bubble column bioreactors an appealing choice for smaller scale applications. Additionally, their scalability and low operational costs contribute to their increasing adoption in various fermentation processes, further driving market growth in that segment.

Pneumatic Bioreactors:

Pneumatic Bioreactors utilize gas flow to create mixing and aeration within the culture medium, which is essential for maintaining cell viability and productivity. These bioreactors are ideal for high-density cultures and have been gaining traction in the biopharmaceutical industry for the production of complex biologics. The technology facilitates better gas exchange, which is crucial for aerobic cell growth. Their modular design allows for easy scaling, making pneumatic bioreactors suitable for both research and commercial applications. As the biopharmaceutical industry seeks to ramp up production capabilities to meet growing demands, the role of pneumatic bioreactors is becoming increasingly critical.

Fluidized Bed Bioreactors:

Fluidized Bed Bioreactors are designed to suspend solid particles in a fluidized state, promoting efficient mass transfer and reaction rates. This type of bioreactor is particularly useful for applications involving immobilized cells or enzymes, making it ideal for continuous bioprocessing. Fluidized bed systems have garnered attention in the production of enzymes and bioactive compounds, as they enhance product yield and process efficiency. Their unique design allows for effective control of process parameters, which is essential for achieving desired outcomes in biotechnological applications. The ongoing trend towards optimizing bioprocessing techniques is expected to bolster the use of fluidized bed bioreactors in the future.

By Application

Biopharmaceuticals:

The application of Single Use Bioreactors in the biopharmaceuticals sector has been a key driver of market growth. These bioreactors facilitate the production of a wide range of therapeutic proteins, monoclonal antibodies, and other biologics that are crucial for treating various diseases. The growing prevalence of chronic and infectious diseases has led to a surge in biopharmaceutical development, thereby increasing the demand for efficient and scalable production technologies. Single use systems offer significant advantages such as reduced risk of contamination and lower capital expenditure, making them an attractive option for biopharmaceutical manufacturers. As the market continues to evolve, the need for innovative and adaptable bioprocessing solutions will remain prevalent, further reinforcing the role of single use bioreactors in this segment.

Vaccine Production:

Vaccine production is another rapidly growing application for Single Use Bioreactors, especially highlighted by the recent global health crises. The urgency for efficient vaccine development and production processes has propelled the adoption of single-use technologies, which enable faster turnaround times and enhanced flexibility in manufacturing. These bioreactors are particularly suitable for growing viral vectors necessary for vaccine development, allowing for rapid and scalable production. The increasing focus on pandemic preparedness and the rising number of vaccine candidates in development necessitate advanced bioprocessing solutions, position Single Use Bioreactors as an essential component in the future of vaccine production.

Cell Culture Research:

Single Use Bioreactors play a significant role in cell culture research, providing researchers with a versatile platform for studying various cell types. These systems enable precise control over environmental conditions, allowing for optimized growth and experimentation. As the focus on personalized medicine and regenerative therapies continues to increase, the need for advanced cell culture techniques has become paramount. The scalability of single-use systems allows researchers to transition from laboratory-scale studies to larger production volumes efficiently. Consequently, the application of Single Use Bioreactors in cell culture research is expected to expand further, driven by innovation and evolving research methodologies.

Regenerative Medicine:

In the field of regenerative medicine, Single Use Bioreactors are utilized for the production of stem cells and other therapeutic cell types essential for tissue engineering and transplantation. These bioreactors provide a controlled environment to promote cell growth and differentiation, making them invaluable for developing advanced therapies. The shift towards personalized treatment approaches necessitates flexible and efficient bioprocessing capabilities, which single-use technologies can provide. As the regenerative medicine sector continues to grow, the adoption of Single Use Bioreactors is likely to increase, supporting advancements in cell-based therapies and tissue engineering.

Others:

The 'Others' category encompasses a range of applications where Single Use Bioreactors are utilized, including the production of biofuels, enzyme production, and the manufacturing of various biochemicals. These diverse applications highlight the versatility and adaptability of single-use bioreactor systems in meeting various industry needs. The continuous innovation in bioprocessing technologies is expected to expand the range of applications for Single Use Bioreactors, driving further growth in this segment. Companies are increasingly exploring novel uses for bioreactors, leading to new opportunities for market expansion and diversification of product offerings.

By End User

Biopharmaceutical Companies:

Biopharmaceutical companies represent one of the largest end-user segments for Single Use Bioreactors, leveraging these technologies to streamline their production processes and meet the increasing demand for biologics. As these companies strive to develop and manufacture advanced therapies, the adoption of single-use systems allows them to enhance productivity while minimizing operational risks associated with cross-contamination. The flexibility of single-use bioreactors also supports the development of diverse product pipelines, enabling biopharmaceutical firms to adapt to changing market demands rapidly. As the sector shifts towards more efficient production methodologies, the reliance on Single Use Bioreactors is expected to intensify.

Contract Development and Manufacturing Organizations:

Contract Development and Manufacturing Organizations (CDMOs) are increasingly adopting Single Use Bioreactors to meet the diverse needs of their clients in the biopharmaceutical space. These organizations are tasked with providing flexible and scalable production solutions, and single-use technologies offer a streamlined approach to manufacturing that reduces time-to-market for their clients' products. By utilizing single-use systems, CDMOs can minimize facility requirements and capital investments, allowing them to offer competitive pricing and enhanced service offerings. The growing trend of outsourcing in the biopharmaceutical industry further reinforces the role of CDMOs in adopting single-use bioreactors.

Research Institutes:

Research institutes are another vital end user of Single Use Bioreactors, utilizing these systems for various research and development purposes. The ability to control and monitor bioprocess parameters makes single-use bioreactors ideal for academic and industrial research settings. Researchers benefit from the reduced risk of contamination and the ease of switching between different experiments without extensive cleaning protocols. As the demands for innovative therapies and biotechnological advancements increase, research institutes will likely continue to explore and implement single-use bioreactor technologies to accelerate their findings and contribute to the broader biopharmaceutical landscape.

Others:

The 'Others' category for End Users includes various entities such as biotechnology firms, small-scale producers, and educational institutions that utilize Single Use Bioreactors for specific applications. These organizations often seek the advantages of single-use systems, including flexibility, ease of use, and lower capital investments. The growing entrepreneurial landscape in biotechnology and the increasing interest in developing innovative products will drive the adoption of Single Use Bioreactors among these diverse user groups. As the market evolves, more entities are likely to recognize the value of single-use technologies, further expanding the market reach.

By Cell Type

Mammalian Cells:

Mammalian cells are one of the primary cell types utilized in Single Use Bioreactors, especially for the production of therapeutic proteins and monoclonal antibodies. These cells require specific growth conditions and nutrient media, which single-use bioreactors can accommodate effectively. The ability to tailor environments for mammalian cell cultures enhances productivity while minimizing contamination risks. With the increasing focus on biopharmaceutical development targeting complex diseases, the demand for mammalian cell-based production systems is expected to rise, thereby driving the growth of Single Use Bioreactors designed for these applications.

Bacterial Cells:

Bacterial cells represent another significant segment in the Single Use Bioreactors market, primarily for applications in biotechnology and microbiology. These cells are commonly used in the production of enzymes, biofuels, and various biochemicals. Single Use Bioreactors provide an efficient platform for growing bacterial cultures, offering benefits such as reduced contamination risk and simplified cleaning processes. The continued advancements in genetic engineering and synthetic biology are anticipated to boost the demand for bacterial cell cultures, further enhancing the importance of single-use technologies in this area.

Yeast Cells:

Yeast cells are extensively utilized in Single Use Bioreactors for various applications, including bioethanol production, brewing, and the synthesis of bioactive compounds. Their robustness and ability to grow in diverse conditions make yeast an ideal choice for industrial applications. Single use systems allow for the efficient handling of yeast cultures, enhancing yield and simplifying the fermentation processes. As the demand for sustainable and renewable resources grows, the use of yeast cells in bioprocessing is expected to expand, positively impacting the Single Use Bioreactor market.

Other Cells:

The 'Other Cells' segment encompasses a variety of cell types employed in Single Use Bioreactors, including insect cells and plant cells, which are used for specific bioprocessing needs. These unconventional cell types are gaining traction in biopharmaceutical applications due to their unique advantages in producing complex biologics and vaccines. Single use bioreactors facilitate the cultivation of these cells under controlled conditions, ensuring optimal growth and product quality. As biotechnological innovations continue to evolve, the exploration of alternative cell systems is expected to drive further adoption of Single Use Bioreactors in this segment.

By Region

The regional analysis of the Single Use Bioreactors market reveals significant growth across various geographies. North America holds the largest market share, accounting for approximately 40% of the global market in 2022. The presence of leading biopharmaceutical companies and research institutions in the region is a key driver fueling this growth. Moreover, the increasing investment in biotechnology research and the rising demand for efficient manufacturing processes are further enhancing market prospects in North America. The CAGR for this region is projected to be around 9.5% over the forecast period, indicating robust growth potential.

In Europe, the Single Use Bioreactors market is experiencing substantial growth, driven by an increasing focus on biomanufacturing and advancements in biotechnological research. Europe accounted for roughly 30% of the global market share in 2022. The European Union's support for biotechnology and innovative health solutions is boosting the adoption of single-use technologies in biopharmaceutical production. Additionally, the rising emphasis on sustainable practices in manufacturing is expected to propel the growth of single-use bioreactors in the region. The market is projected to grow at a CAGR of 8% during the forecast period.

Opportunities

The Single Use Bioreactors market presents numerous opportunities for stakeholders seeking to innovate and enhance their product offerings. The ongoing shift towards personalized medicine and advanced therapy medicinal products (ATMPs) necessitates the development of flexible production systems capable of accommodating diverse bioprocessing needs. Single use technologies can provide the required scalability and adaptability for manufacturers looking to meet the specific demands of personalized treatments. Additionally, with the increasing prevalence of chronic diseases globally, there is a growing need for novel biopharmaceutical products that can be efficiently produced using advanced bioreactor systems. This trend represents a significant opportunity for companies operating in the Single Use Bioreactors market to capitalize on emerging therapeutic needs.

Furthermore, the rise in collaboration and partnerships between biopharmaceutical companies and technology providers is creating additional avenues for growth. As manufacturers seek to enhance their bioprocessing capabilities, collaborations can lead to the development of innovative bioreactor systems that improve efficiency and reduce costs. Companies focusing on research and development are well-positioned to leverage these partnerships to create cutting-edge single-use technologies that cater to evolving market demands. The expansion of manufacturing facilities in emerging markets also represents a prime opportunity for the Single Use Bioreactors market, providing access to new customer bases and increasing overall market penetration.

Threats

Despite the promising growth trajectory of the Single Use Bioreactors market, several threats could potentially hinder its progress. One of the primary concerns is regulatory challenges associated with the approval of biopharmaceutical products produced using single-use systems. Regulatory bodies require stringent validation processes to ensure that products manufactured in single-use bioreactors meet safety and efficacy standards. Delays in obtaining regulatory approvals can impede market entry for new products and slow down overall industry growth. Moreover, the rapid pace of technological advancements necessitates that manufacturers continuously adapt to changing regulations, which can pose a challenge for smaller companies lacking the necessary resources.

Another significant threat involves the potential for supply chain disruptions affecting the availability of single-use components and materials. The reliance on specific suppliers for single-use bioreactor disposables can lead to vulnerabilities in manufacturing processes. Any interruptions in the supply chain can impact production schedules and lead to significant financial losses for companies relying on just-in-time manufacturing practices. Furthermore, increasing competition from alternative bioprocessing technologies, such as reusable bioreactors, may challenge the market position of single-use systems. As organizations seek to balance cost-effectiveness with efficiency, the demand for traditional bioreactor systems may see a resurgence, impacting the growth of single-use bioreactors.

Competitor Outlook

• Thermo Fisher Scientific
• Eppendorf AG
• GE Healthcare
• Merck KGaA
• Danaher Corporation
• Repligen Corporation
• Waters Corporation
• Lonza Group
• Sartorius AG
• Pall Corporation
• ABEC Inc.
• Finesse Solutions
• KUBio (GE)
• Biotechne Corporation
• Corning Incorporated

The competitive landscape of the Single Use Bioreactors market is characterized by a mix of established players and emerging companies that are vying to capture market share through innovation and strategic partnerships. Key competitors are focusing on enhancing their product offerings by investing in research and development to create advanced bioreactor systems that address the specific needs of biopharmaceutical manufacturers. Collaboration with biopharmaceutical companies and institutions is becoming increasingly common as organizations seek to leverage each other's expertise and resources to develop cutting-edge bioprocessing technologies. Moreover, companies are expanding their geographical reach to tap into emerging markets, thereby enhancing their competitive positioning in the global landscape.

Thermo Fisher Scientific, a leading player in the market, is recognized for its extensive portfolio of single-use bioreactor products and services. The company has invested significantly in developing scalable and efficient bioreactor technologies that cater to the diverse needs of biopharmaceutical companies. Furthermore, Thermo Fisher has established a strong global presence, allowing it to serve a wide range of clients in various regions. Eppendorf AG is another key competitor known for its innovative bioprocessing solutions, including single-use technologies. The company focuses on providing flexible and customizable systems that enable researchers and manufacturers to optimize their bioprocesses.

GE Healthcare is also a major player in the Single Use Bioreactors market, offering advanced bioprocessing technologies that enhance the efficiency of biopharmaceutical production. The company has developed a strong portfolio of single-use bioreactors and related equipment, positioned to meet the evolving needs of the biopharmaceutical industry. Merck KGaA, with its extensive experience in bioprocessing, provides a comprehensive range of single-use bioreactor solutions, focusing on quality and scalability. The company's dedication to innovation and collaboration with customers has positioned it as a significant player in the market, ensuring it remains competitive in this fast-evolving landscape.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 ABEC Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 KUBio (GE)
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Merck KGaA
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Lonza Group
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Eppendorf AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sartorius AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 GE Healthcare
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Pall Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Finesse Solutions
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Waters Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Danaher Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Corning Incorporated
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Repligen Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Biotechne Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Thermo Fisher Scientific
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Single Use Bioreactors Sales Market, By End User
    • 6.1.1 Biopharmaceutical Companies
    • 6.1.2 Contract Development and Manufacturing Organizations
    • 6.1.3 Research Institutes
    • 6.1.4 Others
  • 6.2 Single Use Bioreactors Sales Market, By Cell Type
    • 6.2.1 Mammalian Cells
    • 6.2.2 Bacterial Cells
    • 6.2.3 Yeast Cells
    • 6.2.4 Other Cells
  • 6.3 Single Use Bioreactors Sales Market, By Application
    • 6.3.1 Biopharmaceuticals
    • 6.3.2 Vaccine Production
    • 6.3.3 Cell Culture Research
    • 6.3.4 Regenerative Medicine
    • 6.3.5 Others
  • 6.4 Single Use Bioreactors Sales Market, By Product Type
    • 6.4.1 Stirred Tank Bioreactors
    • 6.4.2 Wave-Induced Bioreactors
    • 6.4.3 Bubble Column Bioreactors
    • 6.4.4 Pneumatic Bioreactors
    • 6.4.5 Fluidized Bed Bioreactors

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Single Use Bioreactors Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Single Use Bioreactors Sales market is categorized based on

By Product Type

• Stirred Tank Bioreactors
• Wave-Induced Bioreactors
• Bubble Column Bioreactors
• Pneumatic Bioreactors
• Fluidized Bed Bioreactors

By Application

• Biopharmaceuticals
• Vaccine Production
• Cell Culture Research
• Regenerative Medicine
• Others

By End User

• Biopharmaceutical Companies
• Contract Development and Manufacturing Organizations
• Research Institutes
• Others

By Cell Type

• Mammalian Cells
• Bacterial Cells
• Yeast Cells
• Other Cells

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific
• Eppendorf AG
• GE Healthcare
• Merck KGaA
• Danaher Corporation
• Repligen Corporation
• Waters Corporation
• Lonza Group
• Sartorius AG
• Pall Corporation
• ABEC Inc.
• Finesse Solutions
• KUBio (GE)
• Biotechne Corporation
• Corning Incorporated